凯莱英(002821) - 2019 Q3 - 季度财报

Important Notice The company's Board of Directors, Supervisory Board, and senior management ensure the truthfulness, accuracy, and completeness of this quarterly report and assume legal responsibility - The company's Board of Directors, Supervisory Board, and all senior management ensure the truthfulness, accuracy, and completeness of this quarterly report and commit to legal responsibility. All directors attended the board meeting for reviewing this quarterly report[3] Company Profile Key Accounting Data and Financial Indicators The company achieved strong growth in the first three quarters of 2019, with operating revenue and net profit attributable to shareholders increasing by 44.61% and 40.48% year-on-year, respectively 2019 Core Financial Data for the First Three Quarters | Indicator | Year-to-Date (Yuan) | Year-on-Year Change | | :--- | :--- | :--- | | Operating Revenue | 1,742,485,147.45 | 44.61% | | Net Profit Attributable to Shareholders | 366,515,484.88 | 40.48% | | Net Profit Attributable to Shareholders (Excluding Non-recurring Gains and Losses) | 337,749,587.22 | 38.97% | | Net Cash Flow from Operating Activities | 351,016,576.55 | 28.54% | | Basic Earnings Per Share (Yuan/share) | 1.60 | 39.13% | Asset Situation at Report End | Indicator | End of Reporting Period (Yuan) | Change from Previous Year-End | | :--- | :--- | :--- | | Total Assets | 3,568,241,843.73 | 12.02% | | Net Assets Attributable to Shareholders | 2,855,121,165.34 | 13.72% | - Non-recurring gains and losses totaled 28.77 million Yuan for the period from the beginning of the year to the end of the reporting period, primarily consisting of 32.70 million Yuan in government subsidies[5][6] Shareholder Information As of the end of the reporting period, the total number of common shareholders was 12,708, with the largest shareholder being ASYMCHEM LABORATORIES, INCORPORATED, holding 41.59% - As of the end of the reporting period, the total number of common shareholders was 12,708[7] Top Five Shareholders' Shareholding | Shareholder Name | Shareholder Nature | Shareholding Percentage | Number of Shares Held | | :--- | :--- | :--- | :--- | | ASYMCHEM LABORATORIES, INCORPORATED | Foreign Legal Entity | 41.59% | 96,247,220 | | Hao Hong | Foreign Natural Person | 4.40% | 10,191,928 | | Hong Kong Securities Clearing Company Limited | Foreign Legal Entity | 3.08% | 7,123,208 | | Tianjin Guorong Business Information Consulting Co., Ltd. | Domestic Non-State-Owned Legal Entity | 2.64% | 6,101,796 | | China Merchants Bank Co., Ltd. - Xingquan Flexible Allocation Mixed Securities Investment Fund | Domestic Non-State-Owned Legal Entity | 1.38% | 3,188,402 | Significant Matters Analysis of Changes in Key Financial Data The company experienced significant financial data changes, including a 44.61% increase in operating revenue due to strong CDMO demand, and strategic asset and expense adjustments for business expansion - Operating revenue increased by 44.61% year-on-year, primarily due to the company's continued deep cultivation in the innovative drug CDMO field, with both commercialization and clinical project revenues maintaining rapid growth[12] - Monetary funds decreased by 50.90% from the beginning of the year, primarily used for investment in Haihe Asymchem Fund, 2018 profit distribution, and new capacity construction[12] - Construction in progress increased by 42.50% from the beginning of the year, mainly due to continuous investment in projects such as Jilin Asymchem, Asymchem Life Science, and Shanghai Asymchem Biotechnology[12] - Long-term equity investments increased by 200 million Yuan from zero, mainly due to the current period's investment as an LP in Haihe Asymchem Fund[12] Progress of Significant Matters The company is advancing a private placement plan to raise up to 2.3 billion Yuan, which has been approved by shareholders and accepted by the CSRC, with feedback responses currently being prepared - The company initiated a private placement plan in July 2019, intending to raise a total of no more than 2.3 billion Yuan[14] - The private placement application was accepted by the China Securities Regulatory Commission on August 29, 2019, and a first feedback notice was received on October 11, with responses currently being prepared[14] Other Significant Matters The company maintained compliant operations during the reporting period, with no irregular external guarantees, controlling shareholder fund occupation, or overdue unfulfilled commitments - During the reporting period, the company had no irregular external guarantees, controlling shareholder fund occupation, or entrusted wealth management[18][19][20] Financial Assets Measured at Fair Value (Unit: Yuan) | Asset Category | Initial Investment Cost (Yuan) | Fair Value Change Gain/Loss for the Period (Yuan) | Amount Purchased During the Reporting Period (Yuan) | Period-end Amount (Yuan) | | :--- | :--- | :--- | :--- | :--- | | Financial Derivatives | 7,109,552.98 | -7,109,552.98 | 0.00 | 0.00 | | Other | 0.00 | 0.00 | 20,000,000.00 | 20,000,000.00 | | Total | 7,109,552.98 | -7,109,552.98 | 20,000,000.00 | 20,000,000.00 | Financial Statements Key Financial Statements This section provides the company's consolidated and parent company balance sheets, income statements, and cash flow statements for Q3 2019, reflecting financial position, operating results, and cash flows Balance Sheet (Consolidated) As of September 30, 2019, consolidated total assets were 3.57 billion Yuan, driven by increased construction in progress and long-term equity investments, with a stable financial structure Key Items from Consolidated Balance Sheet (2019-09-30) | Item | Amount (Yuan) | | :--- | :--- | | Total Assets | 3,568,241,843.73 | | Total Liabilities | 713,120,678.39 | | Total Equity Attributable to Parent Company Owners | 2,855,121,165.34 | Income Statement (Consolidated) In the first three quarters of 2019, consolidated operating revenue reached 1.74 billion Yuan, with net profit attributable to parent company owners at 367 million Yuan, demonstrating rapid growth Key Items from Consolidated Income Statement (First Three Quarters of 2019) | Item | Amount (Yuan) | | :--- | :--- | | Total Operating Revenue | 1,742,485,147.45 | | Operating Profit | 412,458,717.15 | | Total Profit | 412,372,565.53 | | Net Profit Attributable to Parent Company Owners | 366,515,484.88 | Cash Flow Statement (Consolidated) In the first three quarters of 2019, consolidated net cash flow from operating activities was 351 million Yuan, while investing activities resulted in a 669 million Yuan net outflow, primarily for asset acquisition and fund investments Key Items from Consolidated Cash Flow Statement (First Three Quarters of 2019) | Item | Amount (Yuan) | | :--- | :--- | | Net Cash Flow from Operating Activities | 351,016,576.55 | | Net Cash Flow from Investing Activities | -668,704,304.94 | | Net Cash Flow from Financing Activities | -38,857,454.22 | | Net Increase in Cash and Cash Equivalents | -356,833,726.42 | Explanation of Financial Statement Adjustments The company adopted new financial instrument accounting standards from January 1, 2019, reclassifying certain financial assets to "Trading financial assets" without impacting total assets, liabilities, or net assets - The company implemented new financial accounting standards from January 1, 2019, reclassifying 7.11 million Yuan from "Financial assets measured at fair value through profit or loss" to "Trading financial assets," with no impact on beginning net assets[49][52]